On December 10, Biogen/Eisai’s controversial Alzheimer’s treatment aducanumab was filed for regulatory approval in Japan. It’s unclear whether Japanese regulators…
HOME > COLUMN
COLUMN
- The Best Recruiters Are Just a Little Paranoid
February 17, 2017
- 5 Killer Questions for HR to Ask Recruiters
January 20, 2017
- What Pharma Can Learn from the Airline Industry
December 16, 2016
- Near Death at Singapore General Hospital and 5 Lessons I Learnt
October 20, 2016
- Reasons for a “Hold”
August 9, 2016
- It’s Time for Market Access to Play a Leading Role
April 22, 2016
- Biosimilars Are the New Black
March 25, 2016
- Technology Provides Opportunities for Medical Device Companies
February 18, 2016
- Don’t Accept the Offer
January 22, 2016
- It’s Your Choice
December 18, 2015
- Ask a Question and Shut Up
November 27, 2015
- Recruiternomics
October 30, 2015
- Pharma Companies in JPAC Are Searching for the Goldilocks Candidate
September 25, 2015
- No… Your Company Is Not like a Family!
August 28, 2015
- What’s Your Pharma Company’s Brand in Japan?
July 24, 2015
- Current Topics of New Drug Development and Marketing in the World: 2
July 10, 2015
- Current Topics of New Drug Development and Marketing in the World: 1
July 9, 2015
- The Mastery of Recruitment
June 26, 2015
- “Every Search Is Won Before It’s Ever Fought”: Sun Tzu
May 22, 2015
- The Truth about Recruiters
April 21, 2015
ページ
With a tumultuous year heading towards a close, let us share the 10 most-read stories on PHARMA JAPAN in 2020. With 2020 being a biennial drug price revision year, our global readers apparently had their eyes riveted on which products…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
As we navigate the lingering effects of the global pandemic, one thing is unmistakably clear - change is here. We’ve changed, and so have our companies. The entire workplace has transformed, but it’s not always a change for the better.…